Charles River

Overview

Charles River, founded in 1947 and based in the United States, operates within the manufacturing sector, specifically focusing on pharmaceuticals and biotechnology. The company employs over 10,000 individuals and generates significant revenue, reflecting its extensive involvement in the biopharmaceutical industry. Charles River's expertise encompasses various aspects of drug development, including the analysis and management of host cell proteins (HCPs), which are critical impurities in biopharmaceuticals. Their published document discusses analytical methods for detecting HCPs, emphasizing the importance of developing specific assays to quantify these proteins throughout the drug development process. The document outlines the challenges associated with HCPs, including their persistence even after purification, and the necessity for customized assay development to ensure product safety and efficacy. Charles River's contributions to the field include both generic and project-specific assays, highlighting their commitment to advancing biopharmaceutical quality control from early development stages to final product release. This focus on analytical methods underscores the company's role in supporting the pharmaceutical industry's regulatory compliance and product integrity.

Industry